Comparison of OS and EFS. Shown is a comparison of OS and EFS in female (A) versus male (B) patients ≥ 60 years of age versus < 60 years; in patients with multilineage dysplasia compared with those without MLD (C); in patients with biallelic versus monoallelic/homozygous CEBPA mutations in the FLT3-ITD⁻ subgroup (D); and in patients with intermediate versus adverse karyotypes according to MRC criteria (E).¹⁶